Litcius/Paper detail

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Ioanna Gouni‐Berthold, Veronica J. Alexander, Qingqing Yang, Eunju Hurh, Elisabeth Steinhagen‐Thiessen, Patrick M. Moriarty, Stephen G. Hughes, Daniel Gaudet, Robert A. Hegele, Louis O’Dea, Erik S.G. Stroes, Sotirios Tsimikas, Joseph L. Witztum, Abhay Kumar Agarwal, Christie M. Ballantyne, Seth J. Baum, Jean Bergeron, Éric Bruckert, Richard K. Burdick, Manuel Castro-Cabezas, Mark Cervi, Clinton N. Corder, Robert Dufour, Cecil Murray Farrington, Gordon Francis, Lawrence Galitz, Steven Hamstead, Linda Hemphill, Cynthia Huffman, Basil Issa, Ulrich Julius, John P. Kane, Michel Krempf, Steven W. Martin, James J. Powell, Richard Shultzaberger, Craig Thompson, Letitia Thompson-Hargrave, Peter P. Tóth, Traci Turner, René Valéro, Bruno Vergès, Frank L.J. Visseren, Pankaj Vyas, Alberto R. Yataco

2021The Lancet Diabetes & Endocrinology226 citationsDOI

Topics & Concepts

MedicinePlaceboClinical trialInternal medicineTriglycerideDosingRandomized controlled trialSurgeryPhysical therapyCholesterolPathologyAlternative medicineLipid metabolism and disordersMetabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial | Litcius